These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 19587552)
21. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Shimada K; Ogihara T; Saruta T; Kuramoto K; Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495 [TBL] [Abstract][Full Text] [Related]
22. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. Clement DL; De Buyzere ML; De Bacquer DA; de Leeuw PW; Duprez DA; Fagard RH; Gheeraert PJ; Missault LH; Braun JJ; Six RO; Van Der Niepen P; O'Brien E; N Engl J Med; 2003 Jun; 348(24):2407-15. PubMed ID: 12802026 [TBL] [Abstract][Full Text] [Related]
23. Blood pressure variability and cardiovascular risk in treated hypertensive patients. Pierdomenico SD; Lapenna D; Di Tommaso R; Di Carlo S; Esposito AL; Di Mascio R; Ballone E; Cuccurullo F; Mezzetti A Am J Hypertens; 2006 Oct; 19(10):991-7. PubMed ID: 17027816 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of an olmesartan medoxomil-based treatment algorithm in patients with hypertension and type 2 diabetes: analysis of diurnal blood pressure control as assessed by 24-hour ambulatory blood pressure monitoring. Kereiakes DJ; Neutel J Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):285-93. PubMed ID: 20801941 [TBL] [Abstract][Full Text] [Related]
25. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Salles GF; Cardoso CR; Muxfeldt ES Arch Intern Med; 2008 Nov; 168(21):2340-6. PubMed ID: 19029499 [TBL] [Abstract][Full Text] [Related]
26. Prevalence and clinical characteristics of isolated-office and true resistant hypertension determined by ambulatory blood pressure monitoring. Ríos MT; Domínguez-Sardiña M; Ayala DE; Gomara S; Sineiro E; Pousa L; Callejas PA; Fontao MJ; Fernández JR; Hermida RC; Chronobiol Int; 2013 Mar; 30(1-2):207-20. PubMed ID: 23077975 [TBL] [Abstract][Full Text] [Related]
27. Can the effectiveness of hypertension management be improved? Ruilope LM Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):689-95. PubMed ID: 23750678 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of ambulatory blood pressure in hypertensive patients with history of cardiovascular disease. Fagard RH; Thijs L; Staessen JA; Clement DL; De Buyzere ML; De Bacquer DA Blood Press Monit; 2008 Dec; 13(6):325-32. PubMed ID: 18756173 [TBL] [Abstract][Full Text] [Related]
29. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Hermida RC; Ayala DE; Mojón A; Fernández JR Am J Hypertens; 2012 Mar; 25(3):325-34. PubMed ID: 22158066 [TBL] [Abstract][Full Text] [Related]
30. Controlling evening BP as well as morning BP is important in hypertensive patients with prediabetes/diabetes: the JMS-1 study. Eguchi K; Matsui Y; Shibasaki S; Hoshide S; Kabutoya T; Ishikawa J; Ishikawa S; Shimada K; Kario K; Am J Hypertens; 2010 May; 23(5):522-7. PubMed ID: 20168303 [TBL] [Abstract][Full Text] [Related]
31. Are there new threshold and goals in the treatment of arterial hypertension? Segura J; Ruilope LM Eur J Clin Invest; 2012 Aug; 42(8):914-20. PubMed ID: 22404687 [TBL] [Abstract][Full Text] [Related]
32. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Mancia G; Bombelli M; Facchetti R; Madotto F; Corrao G; Trevano FQ; Grassi G; Sega R Hypertension; 2007 Jun; 49(6):1265-70. PubMed ID: 17452502 [TBL] [Abstract][Full Text] [Related]
33. Cardiovascular risk of essential hypertension: influence of class, number, and treatment-time regimen of hypertension medications. Hermida RC; Ayala DE; Mojón A; Fernández JR Chronobiol Int; 2013 Mar; 30(1-2):315-27. PubMed ID: 23181712 [TBL] [Abstract][Full Text] [Related]
34. Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes. Moyá A; Crespo JJ; Ayala DE; Ríos MT; Pousa L; Callejas PA; Salgado JL; Mojón A; Fernández JR; Hermida RC; Chronobiol Int; 2013 Mar; 30(1-2):116-31. PubMed ID: 23181613 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Asayama K; Ohkubo T; Metoki H; Obara T; Inoue R; Kikuya M; Thijs L; Staessen JA; Imai Y; Hypertens Res; 2012 Nov; 35(11):1102-10. PubMed ID: 22895063 [TBL] [Abstract][Full Text] [Related]
36. Big Data and Blood Pressure Control: Insights from the PAMELA and BP-CARE Study Cohorts. Bombelli M; Facchetti R; Mancia G; Grassi G Curr Hypertens Rep; 2018 Jul; 20(10):82. PubMed ID: 30051144 [TBL] [Abstract][Full Text] [Related]
37. Relationship of circadian blood pressure and morning blood pressure surge with the severity of metabolic syndrome in newly diagnosed hypertensives. Bastos JM; Bertoquini S; Polónia J Rev Port Cardiol; 2007; 26(7-8):731-41. PubMed ID: 17939582 [TBL] [Abstract][Full Text] [Related]
38. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Hermida RC; Ayala DE; Mojón A; Fernández JR Chronobiol Int; 2010 Sep; 27(8):1629-51. PubMed ID: 20854139 [TBL] [Abstract][Full Text] [Related]
40. Optimizing blood pressure control in hypertension: the need to use ABPM. Schmieder RE; Lehmann MV; Schmidt S Blood Press; 2013 Apr; 22(2):65-72. PubMed ID: 23035939 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]